article Open AccessTop 1% cited
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Journal of Clinical Oncology · 2015 · Vol. 33(17) · pp. 1889–1894
Dirk Schadendorf✉F. Stephen HodiCaroline RobertJeffrey S. WeberKim MargolinOmid HamidDebra A. PattTai‐Tsang Chen(Bristol-Myers Squibb (Germany))David M. Berman(Bristol-Myers Squibb (Germany))Jedd D. Wolchok
Abstract
To our knowledge, this is the largest analysis of OS to date for ipilimumab-treated patients with advanced melanoma. We observed a plateau in the survival curve, beginning at approximately 3 years, which was independent of prior therapy or ipilimumab dose. These data add to the evidence supporting the durability of long-term survival in ipilimumab-treated patients with advanced melanoma.
CAR-T cell therapy researchCutaneous Melanoma Detection and ManagementBiosimilars and Bioanalytical MethodsIpilimumabMedicineInternal medicineMelanomaSurvival analysisProportional hazards modelClinical trialOncologySurgeryCancer
MeSH terms
IpilimumabAntibodies, MonoclonalAntineoplastic AgentsDrug Administration ScheduleFollow-Up StudiesHumansMelanomaProspective StudiesRetrospective StudiesSkin NeoplasmsTreatment OutcomeClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicKaplan-Meier Estimate
Funding
- Amgen
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Institutes of Health
- National Cancer Institute
Citations
2,105
FWCI
129.61
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Science Translational Medicine · 2016 · 2,413 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
Biomedicine & Pharmacotherapy · 2017 · 385 citations
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The Lancet Oncology · 2016 · 1,657 citations
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Cancer Cell · 2015 · 4,168 citations
Mechanisms of resistance to immune checkpoint inhibitors
British Journal of Cancer · 2018 · 1,328 citations
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Annals of Oncology · 2019 · 928 citations
References
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research · 2009 · 3,204 citations
Final Version of 2009 AJCC Melanoma Staging and Classification
Journal of Clinical Oncology · 2009 · 4,551 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.